[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537056":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":21,"locations":27,"responsibleParty":145,"collaborators":147,"id":151,"slug":152,"hasResults":153,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":153,"sex":159,"minAge":160,"maxAge":10,"enrollmentInfo":161,"targetDuration":164,"studyType":165,"phases":10,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},{"fullName":5,"class":6},"BostonGene","INDUSTRY",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Breast cancer",null,"Patients with locally recurrent, unresectable or metastatic breast cancer",{"label":13,"type":10,"description":14,"interventionNames":10},"NSCLC","Patients with unresectable stage III or metastatic non-small cell lung cancer",{"label":16,"type":10,"description":17,"interventionNames":10},"Melanoma","Patients with unresectable or metastatic melanoma",{"label":19,"type":10,"description":20,"interventionNames":10},"Sarcoma","Patients with locally advanced or metastatic sarcoma",[22],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Rheanna Carter, MBA","CONTACT","650-773-0771","rheanna.carter@bostongene.com",[28,49,65,81,97,113,129],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Highlands Oncology Group","RECRUITING","Rogers","Arkansas","72758","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-94.11854,36.33202,{"lat":40,"lon":39},[43,46],{"name":44,"role":24,"phone":10,"phoneExt":10,"email":45},"Adam Torres","ATorres@hogonc.com",{"name":47,"role":48,"phone":10,"phoneExt":10,"email":10},"Eric Schaefer, MD","PRINCIPAL_INVESTIGATOR",{"facility":50,"status":30,"city":51,"state":52,"zip":53,"country":34,"countryCode":35,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Stockton Hematology Oncology Medical Group","Stockton","California","95204",{"type":37,"coordinates":55},[56,57],-121.29078,37.9577,{"lat":57,"lon":56},[60,63],{"name":61,"role":24,"phone":10,"phoneExt":10,"email":62},"Lizbeth Ortiz","lortiz@shomg.net",{"name":64,"role":48,"phone":10,"phoneExt":10,"email":10},"Dheeraj Kodali, MD",{"facility":66,"status":30,"city":67,"state":68,"zip":69,"country":34,"countryCode":35,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Fort Wayne Medical Oncology and Hematology","Fort Wayne","Indiana","46804",{"type":37,"coordinates":71},[72,73],-85.12886,41.1306,{"lat":73,"lon":72},[76,79],{"name":77,"role":24,"phone":10,"phoneExt":10,"email":78},"Phil Huston","phil.hutson@fwmoh.com",{"name":80,"role":48,"phone":10,"phoneExt":10,"email":10},"Sunil Babu, MD",{"facility":82,"status":30,"city":83,"state":84,"zip":85,"country":34,"countryCode":35,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"New Mexico Cancer Center","Albuquerque","New Mexico","87109",{"type":37,"coordinates":87},[88,89],-106.65114,35.08449,{"lat":89,"lon":88},[92,95],{"name":93,"role":24,"phone":10,"phoneExt":10,"email":94},"Valerie Tucker","valeriet@nmohc.com",{"name":96,"role":48,"phone":10,"phoneExt":10,"email":10},"Katherine Sanchez, MD",{"facility":98,"status":30,"city":99,"state":100,"zip":101,"country":34,"countryCode":35,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Oklahoma Cancer Specialists and Research Institute","Tulsa","Oklahoma","74146",{"type":37,"coordinates":103},[104,105],-95.99277,36.15398,{"lat":105,"lon":104},[108,111],{"name":109,"role":24,"phone":10,"phoneExt":10,"email":110},"Ruth Dunn","ruth.dunn@ocsri.org",{"name":112,"role":48,"phone":10,"phoneExt":10,"email":10},"Paul Zito, MD",{"facility":114,"status":30,"city":115,"state":116,"zip":117,"country":34,"countryCode":35,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Oncology Consultants","Houston","Texas","77030",{"type":37,"coordinates":119},[120,121],-95.36327,29.76328,{"lat":121,"lon":120},[124,127],{"name":125,"role":24,"phone":10,"phoneExt":10,"email":126},"Laura Guerra","lguerra@OncologyConsultants.com",{"name":128,"role":48,"phone":10,"phoneExt":10,"email":10},"Julio Peguero, MD",{"facility":130,"status":30,"city":131,"state":132,"zip":133,"country":34,"countryCode":35,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Northwest Medical Specialities","Puyallup","Washington","98373",{"type":37,"coordinates":135},[136,137],-122.2929,47.18538,{"lat":137,"lon":136},[140,143],{"name":141,"role":24,"phone":10,"phoneExt":10,"email":142},"Malee Chhan","mchhan@nwmsonline.com",{"name":144,"role":48,"phone":10,"phoneExt":10,"email":10},"Sibel Blau, MD",{"type":146,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[148],{"name":149,"class":150},"Exigent","UNKNOWN","100537056","bostongene-and-exigent-genomic-insight-study-100537056",false,"NCT06272864","BostonGene and Exigent Genomic INsight Study","BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting","BEGIN","Inclusion Criteria:\n\n* Patients must have a confirmed malignancy of:\n\nLocally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or; Unresectable or metastatic melanoma or; Locally advanced or metastatic l sarcoma.\n\n* Life expectancy \\> 3 months as per the treating physician\n* Willingness to provide informed consent\n* Living in the United States at time of enrollment\n* Agree to participate in genomic and molecular profiling\n\nExclusion Criteria:\n\n* not meeting the inclusion criteria","ALL","18 Years",{"count":162,"type":163},400,"ESTIMATED","2 Years","OBSERVATIONAL","The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.",[168,169,16,19],"Breast Cancer","Non-small Cell Lung Cancer",[171,172,173,174],"Comprehensive Molecular Testing","BostonGene Tumor Portrait Test","Molecularly Matched Therapy","DNA and RNA Targets","2025-02-14",{"date":177,"type":178},"2025-02-17","ACTUAL",{"date":180,"type":178},"2024-04-08",{"date":182,"type":163},"2028-01-08",{"name":5,"class":6},7]